| JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer Y Xiang, Z Zhu, G Han, X Ye, B Xu, Z Peng, Y Ma, Y Yu, H Lin, AP Chen, ... Proceedings of the National Academy of Sciences 104 (49), 19226-19231, 2007 | 438 | 2007 |
| JMJD3 is a histone H3K27 demethylase Y Xiang, Z Zhu, G Han, H Lin, L Xu, CD Chen Cell research 17 (10), 850-857, 2007 | 353 | 2007 |
| DNA-PKcs-mediated transcriptional regulation drives prostate cancer progression and metastasis JF Goodwin, V Kothari, JM Drake, S Zhao, E Dylgjeri, JL Dean, ... Cancer cell 28 (1), 97-113, 2015 | 176 | 2015 |
| Dual-specificity histone demethylase KIAA1718 (KDM7A) regulates neural differentiation through FGF4 C Huang, Y Xiang, Y Wang, X Li, L Xu, Z Zhu, T Zhang, Q Zhu, K Zhang, ... Cell research 20 (2), 154-165, 2010 | 133 | 2010 |
| PHF8 is a histone H3K9me2 demethylase regulating rRNA synthesis Z Zhu, Y Wang, X Li, Y Wang, L Xu, X Wang, T Sun, X Dong, L Chen, ... Cell research 20 (7), 794-801, 2010 | 99 | 2010 |
| Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer J Li, M Alyamani, A Zhang, KH Chang, M Berk, Z Li, Z Zhu, M Petro, ... Elife 6, e20183, 2017 | 97 | 2017 |
| Phf8 histone demethylase deficiency causes cognitive impairments through the mTOR pathway CDC Xuemei Chen, Shuai Wang, Ying Zhou, Yanfei Han, Shengtian Li, Qing Xu ... Nature Communications 9 (114), 2018 | 56 | 2018 |
| Functional silencing of HSD17B2 in prostate cancer promotes disease progression X Gao, C Dai, S Huang, J Tang, G Chen, J Li, Z Zhu, X Zhu, S Zhou, ... Clinical Cancer Research 25 (4), 1291-1301, 2019 | 43 | 2019 |
| Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues C Dai, YM Chung, E Kovac, Z Zhu, J Li, C Magi-Galluzzi, AJ Stephenson, ... Clinical Cancer Research 23 (20), 6351-6362, 2017 | 36 | 2017 |
| Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging Z Zhu, YM Chung, O Sergeeva, V Kepe, M Berk, J Li, HK Ko, Z Li, M Petro, ... Journal of Biological Chemistry 293 (46), 17829-17837, 2018 | 32 | 2018 |
| The androgen receptor in hormone-refractory prostate cancer HL Mao, ZQ Zhu, CD Chen Asian journal of andrology 11 (1), 69, 2009 | 27 | 2009 |
| Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation J Li, M Berk, M Alyamani, N Sabharwal, C Goins, J Alvarado, ... Science translational medicine 13 (595), eabe8226, 2021 | 22 | 2021 |
| Tet1 is required for Rb phosphorylation during G1/S phase transition S Huang, Z Zhu, Y Wang, Y Wang, L Xu, X Chen, Q Xu, Q Zhang, X Zhao, ... Biochemical and Biophysical Research Communications, 2013 | 14 | 2013 |
| Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation D Cui, J Li, Z Zhu, M Berk, A Hardaway, J McManus, YM Chung, ... The Journal of clinical investigation 133 (7), 2023 | 9 | 2023 |
| BMX controls 3βHSD1 and sex steroid biosynthesis in cancer X Li, M Berk, C Goins, M Alyamani, YM Chung, C Wang, M Patel, N Rathi, ... The Journal of clinical investigation 133 (2), 2023 | 8 | 2023 |
| Hypoxia-reoxygenation couples 3βHSD1 enzyme and cofactor upregulation to facilitate androgen biosynthesis and hormone therapy resistance in prostate cancer L Qin, YM Chung, M Berk, B Naelitz, Z Zhu, E Klein, AA Chakraborty, ... Cancer research 82 (13), 2417-2430, 2022 | 8 | 2022 |
| Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. eLife 6 J Li, M Alyamani, A Zhang, KH Chang, M Berk, Z Li, Z Zhu, M Petro, ... | 6 | 2017 |
| Chronic hypoxia stabilizes 3βHSD1 via autophagy suppression L Qin, M Berk, YM Chung, D Cui, Z Zhu, AA Chakraborty, N Sharifi Cell reports 43 (1), 2024 | | 2024 |
| Abstract A026: BMX inhibition reverses HSD3B1-driven resistance in prostate cancer X Li, M Berk, C Goins, M Alyamani, YM Chung, C Wang, M Patel, N Rathi, ... Cancer Research 83 (11_Supplement), A026-A026, 2023 | | 2023 |
| BMX inhibition and HSD3B1-driven resistance in prostate cancer in the Maverick trial. N Sharifi, RR McKay, J Vinson, MA Royal, JM Lang, EA Klein, X Li, M Berk, ... Journal of Clinical Oncology 41 (6_suppl), 144-144, 2023 | | 2023 |
